ES8802582A1 - Un metodo para estabilizar un precursor de activador de plasminogeno. - Google Patents

Un metodo para estabilizar un precursor de activador de plasminogeno.

Info

Publication number
ES8802582A1
ES8802582A1 ES551324A ES551324A ES8802582A1 ES 8802582 A1 ES8802582 A1 ES 8802582A1 ES 551324 A ES551324 A ES 551324A ES 551324 A ES551324 A ES 551324A ES 8802582 A1 ES8802582 A1 ES 8802582A1
Authority
ES
Spain
Prior art keywords
salts
precursor
plasminogen activator
stabilized
percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES551324A
Other languages
English (en)
Spanish (es)
Other versions
ES551324A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
GC Biopharma Corp
Original Assignee
Green Cross Corp Japan
Green Cross Corp Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan, Green Cross Corp Korea filed Critical Green Cross Corp Japan
Publication of ES551324A0 publication Critical patent/ES551324A0/es
Publication of ES8802582A1 publication Critical patent/ES8802582A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ES551324A 1985-01-30 1986-01-28 Un metodo para estabilizar un precursor de activador de plasminogeno. Expired ES8802582A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60017077A JPS61176532A (ja) 1985-01-30 1985-01-30 プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法

Publications (2)

Publication Number Publication Date
ES551324A0 ES551324A0 (es) 1988-08-16
ES8802582A1 true ES8802582A1 (es) 1988-08-16

Family

ID=11933913

Family Applications (1)

Application Number Title Priority Date Filing Date
ES551324A Expired ES8802582A1 (es) 1985-01-30 1986-01-28 Un metodo para estabilizar un precursor de activador de plasminogeno.

Country Status (6)

Country Link
US (1) US5075230A (enExample)
EP (1) EP0190041A3 (enExample)
JP (1) JPS61176532A (enExample)
KR (1) KR940000540B1 (enExample)
CA (1) CA1283047C (enExample)
ES (1) ES8802582A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940003056B1 (ko) * 1985-04-16 1994-04-13 가부시끼가이샤 미도리 쥬우지 우로키나제 전구체를 안정화시키는 방법
JPH0610139B2 (ja) * 1986-05-15 1994-02-09 エモリ ユニバーシティ 繊維素溶解性合成物混合物及び血管内の血餅溶解用薬剤
JPS62292729A (ja) * 1986-06-12 1987-12-19 Toyobo Co Ltd ヒト子宮組織由来プラスミノ−ゲン活性化因子製剤
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
CA2091544A1 (en) * 1992-03-26 1993-09-27 Shing F. Kwan Stabilization of functional proteins
GB9320782D0 (en) * 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
ES2670969T3 (es) 2012-11-13 2018-06-04 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5137343B2 (enExample) * 1972-12-07 1976-10-15
US4245051A (en) * 1978-03-30 1981-01-13 Rockefeller University Human serum plasminogen activator
NL7812336A (nl) * 1978-12-20 1980-06-24 Methanol Chemie Nederland Bereiding van spaanplaat.
JPS5668607A (en) * 1979-11-07 1981-06-09 Teikoku Hormone Mfg Co Ltd Medical preparation with storage stability
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
JPS58170354A (ja) * 1982-03-30 1983-10-06 Hitachi Ltd リニヤ・アクチユエ−タ
JPS5959629A (ja) * 1982-09-27 1984-04-05 Nippon Chem Res Kk 効力持続性組成物
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
EP0139447B1 (en) * 1983-09-13 1992-12-30 The Green Cross Corporation A process for preparing urokinase zymogen
EP0151996B1 (en) * 1984-01-30 1991-04-03 Asahi Kasei Kogyo Kabushiki Kaisha Process for the preparation of a double-chain plasminogen activator
KR940003056B1 (ko) * 1985-04-16 1994-04-13 가부시끼가이샤 미도리 쥬우지 우로키나제 전구체를 안정화시키는 방법

Also Published As

Publication number Publication date
ES551324A0 (es) 1988-08-16
CA1283047C (en) 1991-04-16
JPS61176532A (ja) 1986-08-08
EP0190041A2 (en) 1986-08-06
JPH0479326B2 (enExample) 1992-12-15
EP0190041A3 (en) 1988-09-28
US5075230A (en) 1991-12-24
KR860005884A (ko) 1986-08-13
KR940000540B1 (ko) 1994-01-24

Similar Documents

Publication Publication Date Title
ES8800343A1 (es) Un metodo para producir una proteina que contiene actividad biologica para coagulacion de sangre, mediada por factor viia
ES8705842A1 (es) Procedimiento para la preparacion biotecnologica de acidos alfa-arilalcanoicos activos opticamente
DE69027526D1 (de) Herstellung von proteinen mittels homologer rekombination
ES8602112A1 (es) Procedimiento para preparar un polipeptido ciclico
Shim Increase in serum haptoglobin stimulated by prostaglandins
SE8000243L (sv) Typ ii-interferon och medel innehallande detsamma
CL2008000584A1 (es) Procedimiento de preparacion de esteres dialquilicos de acidos alquil-amido-tiofosforicos que comprende la reaccion de un ditiofosfato con agente de oxidacion en solucion de caracter acido y reaccion del producto obtenido con una amina (divisional de
ES2133163T3 (es) Esteres (o tioesteres) del acido n-acilsulfamico y esteres (o tioesteres) del acido n-sulfonilcarbamico como agentes hipercolesterolemicos.
EA199800943A1 (ru) Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы
DK176285A (da) Fremstilling af polypeptider med human-gamma-interferonaktivitet
MX2025011493A (es) Composiciones y metodos para el direccionamiento a pcsk9
GB1522006A (en) Feline calicivirus vaccine and a process for the production thereof
ES2043610T3 (es) Procedimiento para la produccion de un polipeptido hibrido del tipo activador de plasminogeno.
ES482856A1 (es) Un procedimiento para sintetizar enzimaticamente acido ribo-nucleico de doble cadena
EP0190041A3 (en) Stabilized plasminogen activator precursor and method of producing the same
RU94043769A (ru) Способ повышения продукции протеина с, способ повышения уровня его модификации
MX173840B (es) Procedimiento para producir una enzima de alfa-amilasa
NO884549D0 (no) Fremgangsmaate ved fremstilling av proteiner.
ES8706821A1 (es) Metodo de estabilizar un precursor de uroquinasa
ES2042988T3 (es) Acidos 1h-indazol-3-aceticos como inhibidores de aldosareductasa.
DK627587A (da) Fremgangsmaade til fremstilling af 2-arylprpionsyrer og mikroorganismer anvendt ved denne fremgangsmaade
NO890761L (no) Nye tiorodaminer og en ny fremgangsmaate for deres fremstilling.
FI102844B1 (fi) Menetelmä valmistaa parannettu terapeuttisesti aktiivinen kudosplasminogeenin aktivaattori
DE3781775D1 (de) Racematspaltung von 3-acyloxy-bicyclo(3.3.0)octan-7-on-2-carbonsaeureestern durch stereospezifische enzymatische oder mikrobiologische acylat-hydrolyse.
IT1223302B (it) Composti solfonamido derivati inibitori del sistema enzimatico aldoso-reduttasi e composizioni farmaceutiche che li contengono

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970505